%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
98 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-07-05T16:01:16Z
2024-03-28T07:23:19-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T07:23:19-07:00
application/pdf
Heather
2005-421.aug
uuid:33e31c95-1dd2-11b2-0a00-d50827bd7700
uuid:33e31c98-1dd2-11b2-0a00-900000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
108 0 obj
[112 0 R]
endobj
109 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.12489 Tw 10 0 0 10 53.468 735.6616 Tm
[(ically relevant? )17.6 (While not all data support the interaction,)]TJ
0.19189 Tw 0 -1.2 TD
(there is substantial evidence, and many other therapeutic)Tj
0.14771 Tw T*
(options to recommend against using ibuprofen in patients)Tj
-0.0036 Tw T*
[(requiring cardioprotective aspirin. )17.7 (What are the other choic-)]TJ
0.0061 Tw T*
[(es? Catella-Lawson\325)54.8 (s initial work)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 187.7662 690.9616 Tm
(10)Tj
-0.00011 Tc 0.0061 Tw 10 0 0 10 197.8276 687.6616 Tm
(suggests that diclofenac)Tj
-0.0278 Tw -14.436 -1.2 Td
[(and acetaminophen do not block aspirin\325)54.8 (s ef)17.7 (fect on platelets.)]TJ
0.1917 Tw T*
(As well, other studies suggest no strong interaction with)Tj
0.01489 Tw T*
[(meloxicam or celecoxib. However)39.7 (, we have little or no data)]TJ
0.02499 Tw T*
(about many other commonly used NSAID.)Tj
0.08659 Tw 1.2 -1.2 Td
(While this potential interaction may seem to be of only)Tj
-0.0088 Tw -1.2 -1.2 Td
(academic interest, many rheumatic disease patients are at an)Tj
0.3349 Tw T*
(increased risk of cardiovascular events. Some of these)Tj
0.25841 Tw T*
(patients are at an increased risk presumably because of)Tj
0.3663 Tw T*
(chronic systemic inflammation, while others are at an)Tj
0.2132 Tw T*
(increased risk because of older age, elevated body mass)Tj
0.0885 Tw T*
[(index, and/or reduced physical activity)64.8 (. )17.7 (These issues make)]TJ
0.00391 Tw T*
(many of our patients good candidates for aspirin and should)Tj
0.2274 Tw T*
(make us think twice before suggesting coprescription of)Tj
0 Tw T*
(ibuprofen.)Tj
/T1_1 1 Tf
0.02499 Tw 4.16 -2.4 Td
[(DANIEL)-220.2 (H. SOLOMON, )]TJ
/T1_0 1 Tf
6 0 0 6 206.6555 495.6616 Tm
(MD, MPH,)Tj
0.0145 Tw 8 0 0 8 95.068 485.6616 Tm
(Division of Pharmacoepidemiology and Pharmacoeconomics, )Tj
0.02499 Tw 0 -1.25 TD
[(and Division of Rheumatology)64.8 (, Immunology)64.9 (, and )54.8 (Aller)17.7 (gy)64.8 (, )]TJ
T*
[(Brigham and )17.7 (W)79.9 (omen\325)54.8 (s Hospital,)]TJ
T*
(Boston, Massachusetts, USA;)Tj
/T1_1 1 Tf
10 0 0 10 95.068 443.6616 Tm
[(NICOLA)-220.2 (J. GOODSON, )]TJ
/T1_0 1 Tf
0 Tc 6 0 0 6 203.8747 443.6616 Tm
[(MRCP)110.8 (, PhD,)]TJ
-0.00011 Tc 0.0145 Tw 8 0 0 8 95.068 433.6616 Tm
(Division of Pharmacoepidemiology and Pharmacoeconomics,)Tj
0.02499 Tw T*
[(Division of Rheumatology)64.8 (, Immunology)64.9 (, and )54.8 (Aller)17.7 (gy)64.8 (,)]TJ
T*
[(Brigham and )17.7 (W)79.9 (omen\325)54.8 (s Hospital;)]TJ
T*
(and Department of Rheumatology \(NJG\))Tj
T*
[(Division of Infection and Immunity)64.8 (,)]TJ
T*
[(University Hospital )54.8 (Aintree,)]TJ
T*
(Liverpool, UK.)Tj
/T1_2 1 Tf
-5.2 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. D.H. Solomon, Division of)]TJ
T*
[(Pharmacoepidemiology)54.8 (, Brigham and W)91.7 (omen\325)128.8 (s Hospital, 1620 T)54.8 (r)36.9 (emont)]TJ
T*
[(Str)36.8 (eet, Suite 3030, Boston, MA)-257.3 (02120. E-mail: dhsolomon@partners.or)36.8 (g)]TJ
0.10049 Tw T*
[(No specific support for this editorial. Dr)110.7 (. Solomon has r)36.8 (eceived r)36.8 (esear)36.8 (ch)]TJ
0.01421 Tw T*
[(funding fr)36.8 (om Mer)36.8 (ck and Pfizer)110.8 (, but has no personal financial r)36.8 (elationships)]TJ
0.0563 Tw T*
[(with any pharmaceutical company)54.8 (. Other support: NIH grants \(AR48264,)]TJ
0.2737 Tw T*
[(AR48616, DA15507\), the )17.8 (Arthritis Foundation \(Atlanta, GA\), and the)]TJ
0.02499 Tw T*
[(Engalitcheff )17.7 (Arthritis Outcomes Initiative \(Baltimor)36.8 (e, MD\). )]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 53.468 259.6616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 60.468 249.6616 Tm
[(1. )-600.1 (Manzi S, Meilahn EN, Rairie JE, et al. )54.8 (Age-specific incidence rates)]TJ
1.675 -1.25 Td
(of myocardial infarction and angina in women with systemic lupus)Tj
T*
[(erythematosus: comparison with the Framingham Study)64.8 (. )54.8 (Am J)]TJ
T*
(Epidemiol 1997;145:408-15.)Tj
-1.675 -1.25 Td
[(2. )-600.1 (Solomon DH, Karlson EW)91.7 (, Rimm EB, et al. Cardiovascular)]TJ
1.675 -1.25 Td
(morbidity and mortality in women diagnosed with rheumatoid)Tj
T*
(arthritis. Circulation 2003;107:1303-7.)Tj
31.325 68.421 Td
[(3. )-600.1 (Ray JG, Mamdani MM, Geerts )17.7 (WH. Giant cell arteritis and)]TJ
1.675 -1.25 Td
(cardiovascular disease in older adults. Heart 2005;91:324-8.)Tj
0 Tc -1.675 -1.25 Td
[(4. )-600.1 (Symmons DPM, Goodson NJ, Cook MN, )17.7 (W)80 (atson DJ. Men with)]TJ
-0.00011 Tc 1.675 -1.25 Td
(ankylosing spondylitis have an increased risk of myocardial)Tj
T*
[(infarction [abstract]. )54.8 (Arthritis Rheum 2004;50 Suppl:S477.)]TJ
-1.675 -1.25 Td
[(5. )-600.1 (Hansson GK. Inflammation, atherosclerosis, and coronary artery)]TJ
1.675 -1.25 Td
(disease. N Engl J Med 2005;352:1685-95.)Tj
-1.675 -1.25 Td
[(6. )-600.1 (Haara MM, Manninen P)110.7 (, Kroger H, et al. Osteoarthritis of finger)]TJ
1.675 -1.25 Td
(joints in Finns aged 30 or over: prevalence, determinants, and)Tj
T*
[(association with mortality)64.8 (. )54.8 (Ann Rheum Dis 2003;62:151-8.)]TJ
-1.675 -1.25 Td
[(7. )-600.1 (Singh G, Miller JD, Lee FH, Pettitt D, Russell MW)91.7 (. Prevalence of)]TJ
1.675 -1.25 Td
(cardiovascular disease risk factors among US adults with self-)Tj
T*
[(reported osteoarthritis: data from the )17.7 (Third National Health and)]TJ
T*
[(Nutrition Examination Survey)64.8 (. )54.8 (Am J Manag Care 2002;8:383-91.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate)]TJ
1.675 -1.25 Td
(the benefits of aspirin when used for secondary prevention of)Tj
T*
(myocardial infarction. J Rheumatol 2005;32:1589-93.)Tj
0 Tc -1.675 -1.25 Td
[(9. )-600.1 (Rao GH, Johnson GG, Reddy KR, )17.7 (White JG. Ibuprofen protects)]TJ
-0.00011 Tc 1.675 -1.25 Td
(platelet cyclooxygenase from irreversible inhibition by aspirin.)Tj
T*
(Arteriosclerosis 1983;3:383-8.)Tj
-2.175 -1.25 Td
[(10. )-600.1 (Catella-Lawson F)79.7 (, Reilly MP)110.7 (, Kapoor SC, et al. Cyclooxygenase)]TJ
2.175 -1.25 Td
[(inhibitors and the antiplatelet ef)17.7 (fects of aspirin. N Engl J Med)]TJ
0 Tc 0 Tw T*
(2001;345:1809-17.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1. )-600.1 (van R)39.7 (yn J, Kink-Eiband M, Kuritsch I, et al. Meloxicam does not)]TJ
2.1381 -1.25 Td
[(af)17.7 (fect the antiplatelet ef)17.7 (fect of aspirin in healthy male and female)]TJ
T*
(volunteers. J Clin Pharmacol 2004;44:777-84.)Tj
-2.175 -1.25 Td
[(12. )-600.1 (Ouellet M, Riendeau D, Percival MD. )54.8 (A)-220.1 (high level of)]TJ
2.175 -1.25 Td
(cyclooxygenase-2 inhibitor selectivity is associated with a reduced)Tj
T*
(interference of platelet cyclooxygenase-1 inactivation by aspirin.)Tj
T*
[(Proc Natl )54.8 (Acad Sci USA)-220.2 (2001;98:14583-8.)]TJ
-2.175 -1.25 Td
[(13. )-600.1 (Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin)]TJ
0.00729 Tw 2.175 -1.25 Td
[(resistance. )-17.7 (J Thromb Thrombolysis )-17.7 (2002;13:49-56.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(14. )-600.1 (MacDonald )17.7 (TM, )17.7 (W)79.9 (ei L. Ef)17.7 (fect of ibuprofen on cardioprotective)]TJ
2.175 -1.25 Td
[(ef)17.7 (fect of aspirin. Lancet 2003;361:573-4.)]TJ
-2.175 -1.25 Td
[(15. )-600.1 (Kimmel SE, Berlin JA, Reilly M, et al. )17.7 (The ef)17.7 (fects of nonselective)]TJ
2.175 -1.25 Td
(non-aspirin non-steroidal anti-inflammatory medications on the risk)Tj
T*
(of nonfatal myocardial infarction and their interaction with aspirin.)Tj
T*
[(J )54.8 (Am Coll Cardiol 2004;43:985-90.)]TJ
-2.175 -1.25 Td
[(16. )-600.1 (Kurth )17.7 (T)74 (,)-0.1 ( Glynn RJ, )17.7 (W)79.9 (alker )54.8 (AM, et al. Inhibition of clinical benefits)]TJ
2.175 -1.25 Td
(of aspirin on first myocardial infarction by nonsteroidal)Tj
T*
[(antiinflammatory drugs. Circulation 2003;108:1)36.8 (191-5.)]TJ
-2.175 -1.25 Td
[(17. )-600.1 (Curtis JP)110.7 (, )17.7 (W)79.9 (ang )36.8 (YF)79.7 (, Portnay EL, Masoudi F)73.9 (A, Havranek EP)110.7 (,)]TJ
2.175 -1.25 Td
[(Krumholz HM. )54.8 (Aspirin, ibuprofen, and mortality after myocardial)]TJ
T*
[(infarction: retrospective cohort study)64.8 (. BMJ 2003;327:1322-3.)]TJ
-2.175 -1.25 Td
[(18. )-600.1 (Patel )17.7 (TN, Goldber)17.7 (g KC. Use of aspirin and ibuprofen compared)]TJ
2.175 -1.25 Td
[(with aspirin alone and the risk of myocardial infarction. )54.8 (Arch Intern)]TJ
0 Tc T*
(Med 2004;164:852-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19. )-600.1 (Garcia-Rodriguez LA, )17.7 (V)110.8 (aras-Lorenzo C, Maguire )54.8 (A, Gonzalez-)]TJ
2.175 -1.25 Td
[(Perez )54.8 (A. Nonsteroidal antiinflammatory drugs and the risk of)]TJ
T*
(myocardial infarction in the general population. Circulation)Tj
0 Tc 0 Tw T*
(2004;109:3000-6.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
8 0 0 8 541.468 56.4344 Tm
(1417)Tj
ET
0 0 0 0 k
53.532 70.5 203 -16.37 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.8648 Tm
(Solomon, et al: Editorial)Tj
ET
0 0 0 0 k
/GS0 gs
102.585 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
102.585 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\7$a.B$#ikn#j>p)j@PB6F'q+?CCNQ;?r/39_GY41-)c:$>g"%AJtL+CIs.Q>*@T"5Df!X0ddKF*X?IdO#-i[-3Jl
e_AZ*b.1k`Hd8ilHNj%`1USiDm=3G8O9---b!/Ct2&\*$GIn#iH,gc16^\5
L+)0N5NS5d^:`jgr[j30'Di^K8PokY~>
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
48 0 obj
<>
endobj
59 0 obj
<>
endobj
43 0 obj
<>
endobj
91 0 obj
<>
endobj
103 0 obj
<>
endobj
44 0 obj
<>
endobj
67 0 obj
<>stream
H|UyPW{AmnPF"QKG9$F 2\5KԅVlԸQmHحzU_z~߯ED3BBBCCEu^kTe]EL1Hx'+fl{grsRb2ja]E"YecsowR4={Ӹ)7i9xn!]Z|[դhUiq8?1utt*bNT\VR䔴Cx?S%-Lrj;SǩUZu7N#}L$,L&Ʀ1[lM`$"1Vɰ
z1?LubE(JtV,mb^ORkfUlu^zMJmҺM͐mggeNE_`sd
3;c&JASt9
Nu|0M
lh|0e4絧yB}XM'D$dd3rݸ[Fks
P Mjp=VY
Wu_+q.Gȏ5w^%|2DF[G
k`!nы.ə(q].CEC}2DQ/F], J!!\HD <kn?jNJjǷXy~ӸI|nޗ<cI( zD
W\T,W8#Cq&ˎ\Il+s]U^Vˀ;_W)%dJ{JONesXLdG7MwS#"^<&=
5J^F@D07\G7}3Kf.o81By}Elԫ츬FbdG8g Kf6KY7 o&TJhI-gJ_iC?_^+
A#Ԁ
(KhO4>!&|'2q$(Ow=C"~P7C8pGxd /z*$d6kG)NN֟` g9yj%
tU
yN(AJQap{3![
ed10+rX]/#[Q-*tٌV"V+H_|p\1ǐd;2A [b)r=kilV(1NH&%{r\Q^ȷ
B,<r%^Dm/i#=w
athE$M) crNCj=oj3Cr>63cɆTf錙CyY1*Fz
SQ4}kdt4!"Ojsv#W
$ /
mBX0[N٤OT)zu)A[)Y=[:S=Ooچ$n_\K[<36A?ouD.__7}gwBS((1
6'|?J_ .{jr
{6͒ONWP=T}vNN%r Cg@N˲ʫe%pqJx
E|x 5rm^i<5|k"%GRASfAĊ'}w _tYwe)( 93UABQ$$*jcY{S t~臸\c|WIwfUhdz TZ䄗dԂE.PI'%D1хɗ,p*,* 7H#]g33_oRϖHɑokAt^;>5c/